EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Persistent Eosinophilic Inflammation Is Not a Feature of Type 2 CRS Patients Failing Anti‐IL‐5R Therapy and Requiring Class Switching to Anti‐IL‐4/13

Peta-Lee Sacks iD, Christian M Meerwein, Peter Earls, Cedric Thiel, Christine Choy, Raewyn G Campbell, Raymond Sacks, Larry Kalish, Richard J Harvey iD

International Forum of Allergy & Rhinology · 2025

DOI: 10.1002/alr.23534 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Forum of Allergy & Rhinology, 2025. Verfasst von Peta-Lee Sacks und 8 weiteren Autor:innen. Beteiligte Einrichtung: Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, University of New South Wales, Sydney, Australia. Hauptthemen laut MEDLINE: Sinusitis, Antibodies, Monoclonal, Humanized, Rhinitis, Eosinophilia. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Type 2 inflammation dominates eosinophilic chronic rhinosinusitis (eCRS) and adult onset asthma. IL‐4, ‐5, and ‐13 are prominent disease mediators. Disease control can be achieved with biologic therapies. However, despite some patients entering remission, others experience poor control.

Aim

We aimed to describe eCRS patients treated with anti‐IL‐5R antibody (benralizumab) and assess characteristics between responders and those requiring class switching to anti‐IL‐4/13R (dupilumab).

Method

A retrospective cohort study was performed on consecutive adult patients with eCRS and asthma who had commenced benralizumab. Disease control was defined as controlled or poorly controlled (EPOS2020 partly control/uncontrolled). Poorly controlled patients were switched to dupilumab. Baseline and post‐IL‐5R characteristics including age, sex, 22‐item Sinonasal Outcome Test (SNOT‐22), Asthma Control Questionnaire (ACQ) score, and serum/tissue eosinophilia were assessed. Disease control post‐class switching was reassessed. Factors predicting poorly controlled disease on anti‐IL‐5R therapy were sought.

Results

Fifty patients were assessed (51.44 ± 12.73 years, 56% female). Poorly controlled disease on anti‐IL‐5R requiring class switch to dupilumab was seen in 42%. Poorly controlled patients were younger (46.14 ± 10.76 vs. 55.28 ± 12.83 years, p = 0.01) with higher baseline SNOT‐22 (61.42 ± 19.19 vs. 42.32 ± 21.55, p < 0.01). Baseline ACQ scores and eosinophil count (0.78 ± 0.49 vs. 0.62 ± 0.34 × 10 9 cells/L, p = 0.23) and were similar between groups. In the poorly controlled patients on anti‐IL‐5R therapy, eosinophilia had reduced in both serum (0.78 ± 0.5 vs. 0.02 ± 0.1 × 10 9 cells/L, p < 0.01) and tissue (>100 cells/HPF: 100% vs. 29%, p = 0.01). Class switching resulted in disease control for 65%.

Conclusion

Neither eosinophilia nor its reduction predicted a non‐responder group to anti‐IL‐5R therapy. While the eosinophil population may be a good marker for the CRS phenotype seen in nasal polyps, it is unlikely to be the cell population driving the disease process.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SinusitisAntibodies, Monoclonal, HumanizedRhinitisEosinophiliaAsthmaHumansMaleFemaleMiddle AgedRetrospective StudiesChronic DiseaseAdultEosinophilsAgedReceptors, Interleukin-5InflammationDrug Substitution

Stichwörter der Autor:innen

biologicseosinophilsrhinosinusitis

Substanzen

Antibodies, Monoclonal, HumanizedbenralizumabdupilumabReceptors, Interleukin-5

Autor:innen und Institutionen

  • Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, University of New South Wales, Sydney, Australia.
  • Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.
  • Department of Otorhinolaryngology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
  • School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia.
  • Department of Otolaryngology, Head and Neck Surgery, Royal Prince Alfred Hospital, Sydney, Australia.
  • Department of Otolaryngology, Head and Neck Surgery, Concord General Hospital, University of Sydney, Sydney, Australia.

ORCID-Profile: Peta-Lee Sacks, Richard J Harvey

Zitieren

APA

Sacks, P. L., Meerwein, C. M., Earls, P., Thiel, C., Choy, C., Campbell, R. G., Sacks, R., Kalish, L., & Harvey, R. J. (2025). Persistent Eosinophilic Inflammation Is Not a Feature of Type 2 CRS Patients Failing Anti‐IL‐5R Therapy and Requiring Class Switching to Anti‐IL‐4/13. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23534

Vancouver

Sacks PL, Meerwein CM, Earls P, Thiel C, Choy C, Campbell RG, et al. Persistent Eosinophilic Inflammation Is Not a Feature of Type 2 CRS Patients Failing Anti‐IL‐5R Therapy and Requiring Class Switching to Anti‐IL‐4/13. International Forum of Allergy & Rhinology. 2025. doi:10.1002/alr.23534

BibTeX
@article{Sacks2025,
  author = {Sacks, Peta-Lee and Meerwein, Christian M and Earls, Peter and Thiel, Cedric and Choy, Christine and Campbell, Raewyn G and Sacks, Raymond and Kalish, Larry and Harvey, Richard J},
  title = {Persistent Eosinophilic Inflammation Is Not a Feature of Type 2 CRS Patients Failing Anti‐IL‐5R Therapy and Requiring Class Switching to Anti‐IL‐4/13},
  journal = {International Forum of Allergy & Rhinology},
  year = {2025},
  doi = {10.1002/alr.23534}
}
Kostenlos starten →